8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 12, 2026·SEC
Adicet Bio, Inc.(ACET)Earnings, Financials & Key Ratios
ACET•NASDAQ
Price updated Jun 11, 2026
AboutAdicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$116M+4.5%
- Net Income-$117M+0.3%
- EPS (Diluted)-16.95+20.3%
- ROE-67.55%-2.9%
- ROIC-64.87%+39.4%
- Debt/Equity0.09+0.2%
- Interest Coverage-3392.06+88.4%
ACET Key Insights
Adicet Bio, Inc. (ACET) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Profits declining 26.1% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 25.5% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ACET posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACET Price & Volume
Adicet Bio, Inc. (ACET) stock price & volume — 10-year historical chart
Loading chart...
ACET Growth Metrics
Adicet Bio, Inc. (ACET) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM7.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM28.37%
Return on Capital
10 Years-34.57%
5 Years-48.45%
3 Years-64.1%
Last Year-65.71%
ACET Recent Earnings
Adicet Bio, Inc. (ACET) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 13, 2026EPS
$1.88
Est $2.93
+35.8%
Revenue
—
Q2 2026
Mar 12, 2026EPS
$2.94
Est $3.23
+9.0%
Revenue
—
Est $3M
Q4 2025
Nov 5, 2025EPS
$4.64
Est $4.16
-11.5%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$5.44
Est $5.12
-6.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.88vs $2.93+35.8% | — |
| Q2 2026 | Mar 12, 2026 | $2.94vs $3.23+9.0% | —vs $3M |
| Q4 2025 | Nov 5, 2025 | $4.64vs $4.16-11.5% | — |
| Q3 2025 | Aug 7, 2025 | $5.44vs $5.12-6.3% | — |
Based on last 12 quarters of dataView full earnings history →
ACET Peer Comparison
Adicet Bio, Inc. (ACET) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FATE | 229.62M | 1.97 | -1.71 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CELC | 4.36B | 89.49 | -23.67 | -244.61% | 1.94 | |||
 TCRX | 120.03M | 0.92 | -0.92 | 266.65% | -13.61% | -91.94% | 0.76 | |
 IOVA | 1.42B | 3.96 | -3.63 | 60.6% | -123.9% | -50.17% | 0.07 | |
 NTLA | 1.39B | 12.35 | -3.24 | 16.92% | -5.97% | -57.27% | 0.14 | |
 CABA | 490.79M | 3.01 | -1.84 | -131.58% | 0.24 | |||
 ALLO | 458.47M | 1.88 | -2.16 | -100% | -56.45% | 0.26 | ||
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 |
Compare ACET vs Peers
Adicet Bio, Inc. (ACET) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACET Income Statement
Adicet Bio, Inc. (ACET) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 558.52M | 8.18M | 995K | 17.9M | 9.73M | 24.99M | 0 | 0 | 0 | 0 |
Revenue Growth % | 2.12% | -98.54% | -87.84% | 1699.3% | -45.65% | 156.83% | -100% | - | - | - |
Cost of Goods Sold | 5K | 80K | 0 | 0 | 0 | 0 | 0 | 0 | 6.38M | 1.34M |
COGS % of Revenue | 0% | 0.98% | - | - | - | - | - | - | - | - |
Gross Profit | 558.52M▲ 0% | 8.1M▼ 98.5% | 995K▼ 87.7% | 17.9M▲ 1699.3% | 9.73M▼ 45.7% | 24.99M▲ 156.8% | 0▼ 100.0% | 0▲ 0% | -6.38M▲ 0% | -1.34M▲ 0% |
Gross Margin % | 100% | 99.02% | 100% | 100% | 100% | 100% | - | - | - | - |
Gross Profit Growth % | 312.39% | -98.55% | -87.72% | 1699.3% | -45.65% | 156.83% | -100% | - | - | - |
Operating Expenses | 18.88M | 23.14M | 32.38M | 57.09M | 71.16M | 97.54M | 152.04M | 127.61M | 115.73M | 112.46M |
OpEx % of Revenue | 3.38% | 282.91% | 3254.57% | 318.91% | 731.38% | 390.32% | - | - | - | - |
Selling, General & Admin | 2.04M | 8.43M | 8.69M | 22.76M | 22.22M | 26.3M | 26.53M | 28.29M | 22.99M | 20M |
SG&A % of Revenue | 0.36% | 103.02% | 873.57% | 127.13% | 228.37% | 105.22% | - | - | - | - |
Research & Development | 16.84M | 14.72M | 23.69M | 34.33M | 48.94M | 71.25M | 106.04M | 99.32M | 99.13M | 93.8M |
R&D % of Revenue | 3.01% | 179.89% | 2381.01% | 191.78% | 503.01% | 285.1% | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 19.46M | 0 | -6.38M | -1000K |
Operating Income | -18.88M▲ 0% | -14.96M▲ 20.7% | -31.39M▼ 109.8% | -39.19M▼ 24.9% | -61.43M▼ 56.8% | -72.55M▼ 18.1% | -152.04M▼ 109.6% | -127.61M▲ 16.1% | -122.11M▲ 4.3% | -113.8M▲ 0% |
Operating Margin % | -3.38% | -182.91% | -3154.57% | -218.91% | -631.38% | -290.32% | - | - | - | - |
Operating Income Growth % | -1888100% | 20.75% | -109.76% | -24.86% | -56.75% | -18.1% | -109.56% | 16.06% | 4.31% | - |
EBITDA | -18.88M | -14.88M | -30.15M | -37.24M | -59.9M | -67.54M | -145.94M | -121.15M | -115.73M | -107.76M |
EBITDA Margin % | -3.38% | -181.93% | -3030.15% | -208.01% | -615.57% | -270.28% | - | - | - | - |
EBITDA Growth % | -259.33% | 21.15% | -102.57% | -23.52% | -60.84% | -12.77% | -116.07% | 16.99% | 4.47% | 10.3% |
D&A (Non-Cash Add-back) | 5K | 80K | 1.24M | 1.95M | 1.54M | 5.01M | 6.1M | 6.47M | 6.38M | 6.04M |
EBIT | -33.78M | -14.96M | -28.12M | -39.36M | -61.95M | -69.71M | -142.63M | -117.12M | -122.11M | -110.12M |
Net Interest Income | 0 | 543K | 938K | 651K | -85K | 3.68M | 9.95M | 10.71M | 5.74M | 5.38M |
Interest Income | 0 | 543K | 938K | 785K | 91K | 3.76M | 9.95M | 10.71M | 5.78M | 5.44M |
Interest Expense | 7M | 0 | 0 | 134K | 176K | 80K | 0 | 4K | 36K | 59K |
Other Income/Expense | -14.9M | 5.08M | 3.27M | -302K | -691K | 2.76M | 9.38M | 10.49M | 5.31M | 4.97M |
Pretax Income | -33.78M▲ 0% | -9.89M▲ 70.7% | -28.12M▼ 184.4% | -39.49M▼ 40.4% | -62.12M▼ 57.3% | -69.79M▼ 12.3% | -142.66M▼ 104.4% | -117.12M▲ 17.9% | -116.8M▲ 0.3% | -108.83M▲ 0% |
Pretax Margin % | -6.05% | -120.87% | -2826.03% | -220.59% | -638.48% | -279.27% | - | - | - | - |
Income Tax | 0 | -589K | 19K | -2.81M | -125K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 5.96% | -0.07% | 7.13% | 0.2% | 0% | 0% | 0% | 0% | 0% |
Net Income | -33.78M▲ 0% | -9.3M▲ 72.5% | -28.14M▼ 202.6% | -36.68M▼ 30.4% | -62M▼ 69.0% | -69.79M▼ 12.6% | -142.66M▼ 104.4% | -117.12M▲ 17.9% | -116.8M▲ 0.3% | -108.83M▲ 0% |
Net Margin % | -6.05% | -113.67% | -2827.94% | -204.87% | -637.19% | -279.27% | - | - | - | - |
Net Income Growth % | -3377700% | 72.47% | -202.59% | -30.35% | -69.04% | -12.57% | -104.41% | 17.9% | 0.27% | 7.23% |
Net Income (Continuing) | -33.78M | -9.3M | -28.14M | -36.68M | -62M | -69.79M | -142.66M | -117.12M | -116.8M | -108.83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -20.00▲ 0% | -4.96▲ 75.2% | -24.32▼ 390.3% | -80.16▼ 229.6% | -32.00▲ 60.1% | -27.20▲ 15.0% | -52.96▼ 94.7% | -21.28▲ 59.8% | -16.95▲ 20.3% | -10.13▲ 0% |
EPS Growth % | - | 75.2% | -390.32% | -229.61% | 60.08% | 15% | -94.71% | 59.82% | 20.35% | 28.37% |
EPS (Basic) | -20.16 | -4.96 | -24.32 | -80.16 | -32.00 | -27.20 | -52.96 | -21.28 | -16.95 | - |
Diluted Shares Outstanding | 1.69M | 1.86M | 1.16M | 457.5K | 1.93M | 2.57M | 2.69M | 5.49M | 6.89M | 10.74M |
Basic Shares Outstanding | 1.67M | 1.86M | 1.16M | 457.5K | 1.93M | 2.57M | 2.69M | 5.49M | 6.89M | 10.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ACET Balance Sheet
Adicet Bio, Inc. (ACET) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 54.23M | 109.53M | 64.19M | 100.34M | 282.44M | 261.04M | 162.27M | 180.14M | 160.93M | 140.07M |
Cash & Short-Term Investments | 53.35M | 108.03M | 62.4M | 94.61M | 277.54M | 257.66M | 159.71M | 176.3M | 158.53M | 137.59M |
Cash Only | 53.35M | 7.04M | 10.61M | 84.33M | 277.54M | 257.66M | 159.71M | 56.49M | 38.92M | 36.24M |
Short-Term Investments | 0 | 100.99M | 51.79M | 10.28M | 0 | 0 | 0 | 119.81M | 119.61M | 101.35M |
Accounts Receivable | 0 | 0 | 935K | 2.73M | 214K | 435K | 0 | 0 | 342K | 405K |
Days Sales Outstanding | - | - | 342.99 | 55.68 | 8.03 | 6.35 | - | - | - | - |
Inventory | 136.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 1000K | - | - | - | - | - | - | - | - | - |
Other Current Assets | 84K | 15K | 179K | 363K | 2K | 336K | 457K | 474K | 2.05M | 2.07M |
Total Non-Current Assets | 968K | 405K | 17.4M | 53.5M | 56.5M | 69.65M | 45.02M | 40.08M | 31.43M | 29.31M |
Property, Plant & Equipment | 39K | 321K | 2.12M | 25.86M | 35M | 48.98M | 44.2M | 36.75M | 28.48M | 26.36M |
Fixed Asset Turnover | 14321.13x | 25.49x | 0.47x | 0.69x | 0.28x | 0.51x | - | - | - | 0.00x |
Goodwill | 236.97M | 0 | 0 | 20.09M | 19.46M | 19.46M | 0 | 0 | 0 | 0 |
Intangible Assets | 285.08M | 0 | 0 | 1.19M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | -541.5M | 84K | 10.59M | 4.53M | 0 | 0 | 0 | 0 | 2.87M | 11.55M |
Other Non-Current Assets | 929K | 0 | 4.69M | 1.84M | 2.04M | 1.21M | 822K | 3.33M | 76K | 78K |
Total Assets | 55.19M▲ 0% | 109.94M▲ 99.2% | 81.59M▼ 25.8% | 153.84M▲ 88.6% | 338.94M▲ 120.3% | 330.69M▼ 2.4% | 207.29M▼ 37.3% | 220.22M▲ 6.2% | 192.35M▼ 12.7% | 169.38M▲ 0% |
Asset Turnover | 10.12x | 0.07x | 0.01x | 0.12x | 0.03x | 0.08x | - | - | - | 0.00x |
Asset Growth % | -89.79% | 99.19% | -25.79% | 88.55% | 120.33% | -2.43% | -37.31% | 6.23% | -12.65% | -106.36% |
Total Current Liabilities | 5.5M | 5.72M | 14.87M | 22.48M | 16.32M | 19.71M | 19.29M | 19.39M | 21.53M | 18.3M |
Accounts Payable | 1.51M | 538K | 1.05M | 1.55M | 3.26M | 4.4M | 2.63M | 4.83M | 4.74M | 2.93M |
Days Payables Outstanding | 110.59K | 2.45K | - | - | - | - | - | - | 271.08 | 1.04K |
Short-Term Debt | 14.47M | 0 | 0 | 1.22M | 0 | 0 | 0 | 0 | 0 | 2.88M |
Deferred Revenue (Current) | 238K | 0 | 10.99M | 13.98M | 4.8M | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -10.72M | 3.99M | 1.36M | 1.9M | 4.02M | 5.7M | 6.93M | 7.11M | 13.61M | 12.49M |
Current Ratio | 9.86x | 19.16x | 4.32x | 4.46x | 17.31x | 13.25x | 8.41x | 9.29x | 7.47x | 7.65x |
Quick Ratio | -14.93x | 19.16x | 4.32x | 4.46x | 17.31x | 13.25x | 8.41x | 9.29x | 7.47x | 7.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 407.97M | 19K | 127.09M | 21.53M | 19.49M | 18.64M | 17.83M | 14.22M | 11.61M | 11.02M |
Long-Term Debt | 339.2M | 3.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 20.42M | 19.38M | 18.53M | 17.7M | 14.1M | 11.55M | 47.25M |
Deferred Tax Liabilities | 7.33M | 0 | 0 | 125K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -346.52M | -3.09M | 116.2M | 980K | 115K | 114K | 130K | 116K | 62K | 0 |
Total Liabilities | 5.5M | 5.74M | 141.95M | 44.01M | 35.81M | 38.35M | 37.12M | 33.61M | 33.15M | 29.32M |
Total Debt | 353.67M | 3.11M | 0 | 21.64M | 20.94M | 21.02M | 20.92M | 17.23M | 14.74M | 13.9M |
Net Debt | 300.32M | -3.93M | -10.61M | -62.69M | -256.6M | -236.63M | -138.79M | -39.26M | -24.18M | -22.35M |
Debt / Equity | 7.12x | 0.03x | - | 0.20x | 0.07x | 0.07x | 0.12x | 0.09x | 0.09x | 0.10x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.13x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.21x |
Interest Coverage | -4.83x | - | - | -293.72x | -351.98x | -871.38x | - | -29279.50x | -3392.06x | -1866.49x |
Total Equity | 49.69M▲ 0% | 104.2M▲ 109.7% | -60.37M▼ 157.9% | 109.83M▲ 281.9% | 303.13M▲ 176.0% | 292.34M▼ 3.6% | 170.18M▼ 41.8% | 186.61M▲ 9.7% | 159.21M▼ 14.7% | 140.06M▲ 0% |
Equity Growth % | -83.68% | 109.7% | -157.93% | 281.94% | 176.01% | -3.56% | -41.79% | 9.66% | -14.68% | -119.6% |
Book Value per Share | 29.47 | 55.95 | -52.04 | 240.06 | 156.70 | 113.86 | 63.26 | 33.98 | 23.10 | 13.04 |
Total Shareholders' Equity | 49.69M | 104.2M | -60.37M | 109.83M | 303.13M | 292.34M | 170.18M | 186.61M | 159.21M | 140.06M |
Common Stock | 1K | 3K | 0 | 2K | 4K | 4K | 4K | 8K | 10K | 1K |
Retained Earnings | -33.78M | -71.39M | -69.65M | -106.33M | -168.32M | -238.11M | -380.77M | -497.89M | -614.7M | -634.94M |
Treasury Stock | 0 | 129.56M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -5.11M | -41K | 23K | 24K | 0 | 0 | 0 | 16K | 102K | -37K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ACET Cash Flow Statement
Adicet Bio, Inc. (ACET) cash flow — operating, investing & free cash flow history
| Metric | Jun'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.55M | -18.18M | -27.88M | -41.55M | -51.05M | -44.77M | -93.72M | -92.38M | -95.25M | -91.34M |
Operating CF Margin % | -2.07% | -222.22% | -2802.21% | -232.1% | -524.69% | -179.13% | - | - | - | - |
Operating CF Growth % | -238.48% | -57.36% | -53.37% | -49.03% | -22.86% | 12.31% | -109.35% | 1.43% | -3.1% | 13.55% |
Net Income | -33.78M | -9.3M | -28.14M | -36.68M | -62M | -69.79M | -142.66M | -117.12M | -116.8M | -108.83M |
Depreciation & Amortization | 5K | 1.22M | 1.24M | 1.23M | 1.54M | 2.58M | 6.1M | 6.47M | 2.29M | 3.86M |
Stock-Based Compensation | 470K | 2.48M | 1.18M | 5.26M | 12.51M | 17.13M | 20.26M | 22.23M | 14.27M | 11.09M |
Deferred Taxes | 18K | 0 | 0 | 3.2M | 1.23M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 16.57M | -4.54M | -2.5M | -1.04M | 1.72M | 2.58M | 22.33M | 1.57M | 3.53M | 3.22M |
Working Capital Changes | 4.26M | -8.05M | 341K | -13.52M | -6.06M | 2.74M | 252K | -5.53M | 1.47M | -676K |
Change in Receivables | -6.15M | 0 | 0 | 0 | -30K | 185K | 0 | 0 | 0 | 0 |
Change in Inventory | -2.49M | 0 | 0 | 0 | 2.01M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.39M | -282K | 527K | -814K | 1.14M | 1.71M | -1.68M | 1.11M | 1.03M | -1.4M |
Cash from Investing | -44K | -16.06M | -47.93M | 115.22M | -2.8M | -16.78M | -4.46M | -119.24M | 2.39M | 24.13M |
Capital Expenditures | -44K | -876K | -1.07M | -990K | -13.05M | -16.78M | -4.46M | -1.12M | -1.74M | -283K |
CapEx % of Revenue | 0.01% | 10.71% | 107.54% | 5.53% | 134.08% | 67.15% | - | - | - | - |
Acquisitions | 0 | 0 | 118K | 64.11M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -6.71M | -7.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 68M |
Cash from Financing | 64.95M | 11.05M | 76.94M | 303K | 242.69M | 41.51M | 236K | 111.31M | 75.25M | 75.28M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -150K | 0 |
Equity Issued (Net) | 64.95M | 10.82M | 76.92M | 460K | 238.13M | 43.36M | 386K | 110.92M | 75.5M | 75.5M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -55.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 221K | 30K | -157K | 4.56M | -1.85M | -150K | 389K | -104K | -215K |
Net Change in Cash | 30.48M▲ 0% | -23.19M▼ 176.1% | 1.13M▲ 104.9% | 73.97M▲ 6434.3% | 188.84M▲ 155.3% | -20.04M▼ 110.6% | -97.94M▼ 388.8% | -100.31M▼ 2.4% | -17.61M▲ 82.4% | 8.08M▲ 0% |
Free Cash Flow | -11.6M▲ 0% | -19.06M▼ 64.3% | -28.95M▼ 51.9% | -42.54M▼ 46.9% | -64.1M▼ 50.7% | -61.55M▲ 4.0% | -98.18M▼ 59.5% | -93.5M▲ 4.8% | -96.98M▼ 3.7% | -91.62M▲ 0% |
FCF Margin % | -2.08% | -232.93% | -2909.75% | -237.63% | -658.77% | -246.29% | - | - | - | - |
FCF Growth % | -250.1% | -64.32% | -51.93% | -46.94% | -50.67% | 3.98% | -59.52% | 4.77% | -3.73% | 5.83% |
FCF per Share | -6.88 | -10.23 | -24.96 | -92.99 | -33.13 | -23.97 | -36.50 | -17.03 | -14.07 | -8.53 |
FCF Conversion (FCF/Net Income) | 0.34x | 1.96x | 0.99x | 1.13x | 0.82x | 0.64x | 0.66x | 0.79x | 0.82x | 0.84x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 5.11M | 1K | 3K | 43K | 0 | 0 | 0 | 0 | 0 |
ACET Key Ratios
Adicet Bio, Inc. (ACET) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -19.08% | -12.08% | -128.37% | -148.31% | -30.03% | -23.44% | -61.69% | -65.65% | -67.55% | -80.35% |
| Return on Invested Capital (ROIC) | -4.01% | -4.98% | -160.68% | -62.36% | -98.38% | -106.45% | -261.85% | -107.1% | -64.87% | -73.84% |
| Gross Margin | 100% | 99.02% | 100% | 100% | 100% | 100% | - | - | - | - |
| Net Margin | -6.05% | -113.67% | -2827.94% | -204.87% | -637.19% | -279.27% | - | - | - | - |
| Debt / Equity | 7.12x | 0.03x | - | 0.20x | 0.07x | 0.07x | 0.12x | 0.09x | 0.09x | 0.10x |
| Interest Coverage | -4.83x | - | - | -293.72x | -351.98x | -871.38x | - | -29279.50x | -3392.06x | -1866.49x |
| FCF Conversion | 0.34x | 1.96x | 0.99x | 1.13x | 0.82x | 0.64x | 0.66x | 0.79x | 0.82x | 0.84x |
| Revenue Growth | 2.12% | -98.54% | -87.84% | 1699.3% | -45.65% | 156.83% | -100% | - | - | - |
Related:ACET Dividend History·ACET Revenue History·ACET Price History·ACET P/E History·ACET Financial Ratios·ACET Institutional Holders
ACET SEC Filings & Documents
Adicet Bio, Inc. (ACET) SEC filings — annual & quarterly reports (10-K, 10-Q)
ACET Frequently Asked Questions
Adicet Bio, Inc. (ACET) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Adicet Bio, Inc. (ACET) grew revenue by 0.0% over the past year. Growth has been modest.
Adicet Bio, Inc. (ACET) reported a net loss of $108.8M for fiscal year 2025.
Dividend & Returns
Adicet Bio, Inc. (ACET) has a return on equity (ROE) of -67.6%. Negative ROE indicates the company is unprofitable.
Adicet Bio, Inc. (ACET) had negative free cash flow of $91.6M in fiscal year 2025, likely due to heavy capital investments.